4.16
1.89%
-0.08
전일 마감가:
$4.24
열려 있는:
$4.25
하루 거래량:
79,461
시가총액:
$53.91M
수익:
$257.55M
순이익/손실:
$11.95M
주가수익비율:
4.5714
EPS:
0.91
순현금흐름:
$-9.39M
1주 성능:
-9.76%
1개월 성능:
-17.46%
6개월 성능:
-69.52%
1년 성능:
-84.98%
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
명칭
Eagle Pharmaceuticals Inc
전화
201-326-5300
주소
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
2018-11-01 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2018-10-31 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2018-03-21 | 재확인 | Mizuho | Underperform |
2017-11-09 | 재확인 | RBC Capital Mkts | Outperform |
2017-09-06 | 재확인 | Mizuho | Underperform |
2017-07-27 | 재확인 | Mizuho | Underperform |
2017-07-27 | 재확인 | RBC Capital Mkts | Outperform |
2017-05-09 | 재확인 | RBC Capital Mkts | Outperform |
2017-01-09 | 다운그레이드 | Mizuho | Neutral → Underperform |
2016-11-16 | 다운그레이드 | Mizuho | Buy → Neutral |
2016-11-03 | 업그레이드 | Mizuho | Neutral → Buy |
2016-11-03 | 재확인 | RBC Capital Mkts | Outperform |
2016-10-26 | 재확인 | Mizuho | Buy |
2016-08-16 | 재확인 | Mizuho | Neutral |
2016-06-20 | 다운그레이드 | Mizuho | Buy → Neutral |
2016-05-10 | 재확인 | RBC Capital Mkts | Outperform |
2016-03-18 | 재확인 | Mizuho | Buy |
2016-02-26 | 재확인 | Mizuho | Buy |
2015-12-09 | 개시 | Mizuho | Buy |
2015-07-29 | 재확인 | Piper Jaffray | Overweight |
모두보기
Eagle Pharmaceuticals Inc 주식(EGRX)의 최신 뉴스
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
GlobeNewswire Inc.
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
GlobeNewswire Inc.
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City
GlobeNewswire Inc.
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
GlobeNewswire Inc.
Eagle Pharmaceuticals Announces Management Change
GlobeNewswire Inc.
Eagle Pharmaceuticals Inc (EGRX) 재무 분석
Eagle Pharmaceuticals Inc (EGRX) 매출 2024
EGRX은 2023-06-30 종료 분기에 대해 매출(지난 12개월)이 257.55M 달러로 보고했으며, 전년대비 -5.38% 감소했습니다.
Eagle Pharmaceuticals Inc (EGRX) 순이익 2024
EGRX은 2023-06-30 종료 분기에 대해 순이익(지난 12개월)이 11.95M 달러로 보고했으며, 전년대비 -47.57% 감소했습니다.
Eagle Pharmaceuticals Inc (EGRX) 현금흐름 2024
2023-06-30 종료 분기에 EGRX은 현금흐름(지난 12개월)으로 -9.39M 달러를 기록했으며, 전년 대비 -126.60% 감소했습니다.
Eagle Pharmaceuticals Inc (EGRX) 주당 순이익 2024
EGRX이 보고한 2023-06-30 종료 분기의 주당 순이익(지난 12개월)은 0.91달러이며, 전년 대비 -48.30% 감소했습니다.
자본화:
|
볼륨(24시간):